Cargando…

Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment

Immune reconstitution inflammatory syndrome (IRIS) is a common complication during treatment for natalizumab-associated progressive multifocal leukoencephalopathy (PML). Although severe IRIS can result in acute worsening of disability and is associated with poor prognosis, effective immune reconstit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Himedan, Mai, Camelo-Piragua, Sandra, Mills, Elizabeth A., Gupta, Avneesh, Aburashed, Rany, Mao-Draayer, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624358/ https://www.ncbi.nlm.nih.gov/pubmed/28989935 http://dx.doi.org/10.1177/2324709617734248

Ejemplares similares

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Maraviroc in PML-IRIS: A separate ball game under HIV infection and natalizumab?
por: Steiner, Israel, et al.
Publicado: (2017)

Improving risk‐stratification of natalizumab‐associated PML
por: Tugemann, Bastian, et al.
Publicado: (2021)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments
por: Bernard-Valnet, Raphael, et al.
Publicado: (2021)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

An unusual case of miliary PML-IRIS in an HIV+ patient
por: Cuendet, David, et al.
Publicado: (2017)

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
por: Honce, Justin M., et al.
Publicado: (2015)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Neurological complications in HIV patients – a case of PML-IRIS
por: Gliga, Smaranda, et al.
Publicado: (2014)

PML Degradation: Multiple Ways to Eliminate PML
por: Rabellino, Andrea, et al.
Publicado: (2013)

Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
por: Reid, Carl E., et al.
Publicado: (2011)

Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
por: Werner, Milton H., et al.
Publicado: (2016)

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
por: Alleg, Manel, et al.
Publicado: (2020)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study
por: Nishiyama, Shuhei, et al.
Publicado: (2017)

Regulation of NF-κB by PML and PML-RARα
por: Ahmed, Abrar, et al.
Publicado: (2017)

PML and PML-like exonucleases restrict retrotransposons in jawed vertebrates
por: Mathavarajah, Sabateeshan, et al.
Publicado: (2023)

A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together
por: Major, Eugene O., et al.
Publicado: (2016)

7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
por: Sinnecker, Tim, et al.
Publicado: (2015)

PML goes to the centrosome
por: Wells, William A.
Publicado: (2005)

PML, SUMOylation, and Senescence
por: Ivanschitz, Lisa, et al.
Publicado: (2013)

PML Bodies in Mitosis
por: Lång, Anna, et al.
Publicado: (2019)

Circadian behavior of mice deficient in PER1/PML or PER2/PML
por: Miki, Takao, et al.
Publicado: (2013)

Expression and Function of PML-RARA in the Hematopoietic Progenitor Cells of Ctsg-PML-RARA Mice
por: Wartman, Lukas D., et al.
Publicado: (2012)

PML isoforms in response to arsenic: high-resolution analysis of PML body structure and degradation
por: Hands, Katherine J., et al.
Publicado: (2014)

The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA
por: Jaffray, Ellis G., et al.
Publicado: (2023)

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
por: Lieberman, Linda A., et al.
Publicado: (2016)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016)

Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
por: Muñoz-Vendrell, Albert, et al.
Publicado: (2023)

Immunosuppressive therapy in dermatology and PML
por: Sterry, Wolfram, et al.
Publicado: (2009)

Differential Roles of PML Isoforms
por: Nisole, Sébastien, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_knbhuir766kof3m0skp9d8ahpr